Sign up to save your podcasts
Or
Share Ikarovec Raises £2.5M in Seed Funding
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ikarovec Raises £2.5M in Seed Funding
Ikarovec, a Cambridge, UK-based ophthalmic gene therapy company, raised £2.5m in seed funding.
Backers included investors UKI2S, LifeArc and Parkwalk.
In conjunction with the funding, Oliver Sexton, Investment Director at UKI2S, David Holbrook, Head of the Seed Fund at LifeArc, and Dr Cassie Doherty, Investment Director at Parkwalk, joined the baord.
The company intends to use the funds to develop its three earlier stage novel gene therapy products for major ophthalmic indications, build the intellectual property portfolio and establish its own laboratories.
Its lead program is a multicistronic gene therapy for diabetic macular edema (DME), to IND-enabling studies. | To read full story, visit https://startuparound.com/read/1580905823.1853347/Ikarovec-Raises-£2.5M-in-Seed-Funding?ref=audio_experience
View all episodes
By Startup AroundIkarovec, a Cambridge, UK-based ophthalmic gene therapy company, raised £2.5m in seed funding.
Backers included investors UKI2S, LifeArc and Parkwalk.
In conjunction with the funding, Oliver Sexton, Investment Director at UKI2S, David Holbrook, Head of the Seed Fund at LifeArc, and Dr Cassie Doherty, Investment Director at Parkwalk, joined the baord.
The company intends to use the funds to develop its three earlier stage novel gene therapy products for major ophthalmic indications, build the intellectual property portfolio and establish its own laboratories.
Its lead program is a multicistronic gene therapy for diabetic macular edema (DME), to IND-enabling studies. | To read full story, visit https://startuparound.com/read/1580905823.1853347/Ikarovec-Raises-£2.5M-in-Seed-Funding?ref=audio_experience